Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 18, Number 4—April 2012

Dispatch

Neuroinvasive Disease and West Nile Virus Infection, North Dakota, USA, 1999–2008

Paul J. Carson, Stephanie M. Borchardt, Brian Custer, Harry E. Prince, Joan Dunn-Williams, Valerie Winkelman, Leslie Tobler, Brad J. Biggerstaff, Robert Lanciotti, Lyle R. Petersen, and Michael P. BuschComments to Author 
Author affiliations: University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, USA (P.J. Carson, S.M. Borchardt); Sanford Health, Fargo, North Dakota, USA (P.J. Carson); Fargo Veterans Affairs Medical Center, Fargo (S.M. Borchardt); Wisconsin Department of Health, Madison, Wisconsin, USA (S.M. Borchardt); Blood Systems Research Institute, San Francisco, California, USA (B. Custer, L. Tobler, M.P. Busch); Focus Diagnostics, Cypress, California, USA (H.E. Prince); Creative Testing Solutions, Tempe, Arizona, USA (J. Dunn-Williams, V. Winkelman); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (B.J. Biggerstaff, R. Lanciotti, L.R. Petersen); University of California San Francisco, San Francisco (M.P. Busch)

Main Article

Table

Correlation of WNV IgG seroprevalence among blood donors with WNND, by sex and age group, North Dakota, USA, 2002–2008*

Sex and age group, y No. donors Seroprevalence, % (95% CI) Seropositivity, RR (95% CI) Total population† WNV-infected population‡ No. WNND cases§ Ratio of WNND cases to WNV infections (95% CI) WNND, RR (95% CI) Inverse of ratio¶
Male 2,349 9.2 (6.1–8.3) 279,252 26,122 119 0.0045 
(0.0038–0.0054) 220
16–24 321 12.8 (9.1–16.4) Referent 56,156 7,188 10 0.0014 (0.0008–0.0026) Referent 719
25–44 562 8.7 (6.4–11.1) 0.7 (0.5–1.0) 89,968 7,827 22 0.0028 (0.0018–0.0042) 2.0 
(1.0–4.2) 356
45–64 1,132 9.3 (7.6–11.0) 0.7 (0.5–1.0) 90,701 8,435 34 0.0040 (0.0029–0.0056) 2.9 (1.4–5.9) 248
≥65 334 6.3 (3.7–8.9) 0.5 (0.3–0.8) 42.427 2,672 53 0.0198 (0.0152–0.0258) 14.3 (7.3–28.0) 50
Female 2,165 7.2 (6.2–8.3) 271,968 18,353 63 0.0034
(0.0027–0.0044) 291
16–24 316 9.8 (6.5–13.1) Referent 50,274 4,926 4 0.0008 (0.0003–0.09) Referent 1,231
25–44 600 6.7 (4.7–8.7) 0.7 (0.4–1.1) 78,869 5,284 16 0.0030 (0.0018–0.0049) 3.7 (1.2–11.1) 330
45–64 1,010 7.5 (5.9–9.2) 0.8 (0.5–1.1) 87,775 6,583 17 0.0026 (0.0016–0.0042) 3.2 (1.1–9.4) 387
≥65 239 2.9 (0.8–5.1) 0.3 (0.1–0.7) 55,050 1,596 26 0.0163
(0.0111–0.0241) 20.1
(7.0–57.4) 61
Total 4,514 8.2 (7.4–9.0) 551,220 44,511 182 0.0041
(0.0035–0.0047) 244

*WNV, West Nile virus; WNND, WNV neuroinvasive disease; RR, relative risk.
†Source: US Census Bureau, 2010.
‡Seroprevalence × population.
§Data from Centers for Disease Control and Prevention; ArboNET.
¶No. WNV infections/no. WNND cases.

Main Article

Page created: March 14, 2012
Page updated: March 14, 2012
Page reviewed: March 14, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external